Accession Number:

AD1160533

Title:

Topical Nitric Oxide Therapy to Treat Cervical Neoplasias and Prevent HPV-Associated Cancers

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

NOVAN INC DURHAM NC

Personal Author(s):

• Geer, Carri

Report Date:

2021-10-01

Pagination or Media Count:

26

Abstract:

The goal of this research is to develop a nitric oxide-releasing vaginal suppository that can be self-administered by female patients as a treatment for cervical neoplasias to eradicate latent HPV-18 infection and inhibit disease progression to cancer. The suppository will contain our proprietary NO-releasing drug, NVN1000, that has been shown to have antiviral efficacy against HPV-18. We have developed five prototype formulations using excipients determined to be compatible with NVN1000 and appropriate analytical methods for determining formulation stability. From the 12 week stability data, we have selected a lead prototype candidate, although it appears refrigeration will be required to maintain stability. Through our collaborator at the University of Alabama Birmingham, we have also established a NVN1000 dose and application frequency that successfully inhibits HPV-18 replication in infected human raft cultures while minimizing cytotoxity.

Descriptors:

• papillomavirus infections
• test methods
• disease attributes
• dosage forms
• performance tests
• prototypes
• diseases and disorders
• frequency
• manufacturing
• product development
• abstracts
• chemical properties
• infection
• materials
• wound infections
• biomedical research
• chemical stability

Subject Categories:

• Medicine and Medical Research
• Pharmacology

Distribution Statement:

[A, Approved For Public Release]